[Pulmonary hypertension treatment: future prospects].
Baloira
Adolfo
A
D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D000077300:Bosentan; D004353:Drug Evaluation, Preclinical; D065130:Endothelin A Receptor Antagonists; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D006976:Hypertension, Pulmonary / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D016285:Iloprost / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007555:Isoxazoles / Q000627:therapeutic use; D008017:Life Expectancy; D016040:Lung Transplantation; D016686:Monocrotaline / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D011687:Purines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D012756:Sheep; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D065130:Endothelin A Receptor Antagonists; D007555:Isoxazoles; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D011687:Purines; D013449:Sulfonamides; D013450:Sulfones; D013876:Thiophenes; D014665:Vasodilator Agents; D016686:Monocrotaline; D000068677:Sildenafil Citrate; D011464:Epoprostenol; C106276:sitaxsentan; D016285:Iloprost; D000077300:Bosentan; C427248:treprostinil